Palvella Therapeutics (PVLA) Accumulated Depreciation & Amortization (2013 - 2023)

Palvella Therapeutics (PVLA) has 11 years of Accumulated Depreciation & Amortization data on file, last reported at $10.5 million in Q2 2023.

• Quarterly Accumulated Depreciation & Amortization rose 27.6% year-over-year to $10.5 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $10.5 million (up 27.6% YoY) and the FY2022 annual result came in at $9.6 million, up 25.01% from the prior year.
• Accumulated Depreciation & Amortization advanced to $10.5 million in Q2 2023 per PVLA's latest filing, from $10.0 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $10.5 million in Q2 2023 and bottomed at $3.3 million in Q1 2019.
• The 5-year median for Accumulated Depreciation & Amortization is $6.5 million (2021), against an average of $6.4 million.
• The widest annual swing landed in 2019, when Accumulated Depreciation & Amortization grew 2.18%; it then surged 68.16% in 2021.
• Tracing PVLA's Accumulated Depreciation & Amortization over 5 years: stood at $3.6 million in 2019, then surged by 63.02% to $5.8 million in 2020, then surged by 32.71% to $7.7 million in 2021, then climbed by 25.01% to $9.6 million in 2022, then climbed by 9.06% to $10.5 million in 2023.
• Per Business Quant, the three latest PVLA Accumulated Depreciation & Amortization figures stand at $10.5 million (Q2 2023), $10.0 million (Q1 2023), and $9.6 million (Q4 2022).

Peer Comparison